Novo Nordisk ORION Data Shows Oral Semaglutide Outperforms Orforglipron
New ORION study results show oral semaglutide produced greater weight loss and better tolerability than rival orforglipron (Foundayo). Novo also introduced higher-dose Wegovy with aggressive discounts.